Progyny competitors

Mr. George B. Kauffman is a Chairman Chief Executive Officer;Chief Investment Officier at RIGEL PHARMACEUTICALS INC and is based in United States.

Jim Litterer is a President & Chief Executive Officer at Vital Images Inc and is based in Minneapolis, Minnesota. He has worked as Support Operations Analyst at Stellent. Jim studied at Iowa State University between 1998 and 2000 and Iowa State University Ivy College of Business between 1996 and 2000.

R Holmlin is a Board Member at Xagenic Inc, Board Member at Applied Proteomics Inc, and Founder at GENEOHM SCIENCES INC. He has worked as Board Member at BIONANO GENOMICS, INC; President/CEO at Genvault Corp; and Chief Commercial Officer at Exiqon. R works or has worked as Entrepreneur In Residence at Domain Assoc LLC and VP:Marketing & Development at Becton Dickinson. He attended Columbia University, Haas School of Business, and Caltech.

Jigar Raythatha joined Jounce Therapeutics in December 2012 after a 15 year career in the biotechnology industry in a variety business functions. Most recently, Jigar Raythatha was the head of corporate development of Constellation Pharmaceuticals, Inc. where he was instrumental in securing over $175 million in non-dilutive and equity funding. In addition, Jigar Raythatha negotiated and subsequently led the company's broad epigenetics strategic alliance with Genentech and established Constellation's project management and market development capabilities. Prior to Constellation, Jigar Raythatha worked with Red Abbey Venture Partners, initially as a Kauffman fellow, later as a principal, and finally a venture partner. During his tenure at Red Abbey, Jigar Raythatha led or participated in all of the firm's investments, including Advanced BioHealing (acquired by Shire), Aegerion Pharmaceuticals (IPO), Cogenesys (acquired by Teva), and Stromedix (acquired by Biogen Idec). Previously, Jigar Raythatha has worked with Biogen, Inc. and Pfizer, Inc. in business development and new product planning roles. Jigar Raythatha holds an M.B.A. from Columbia Business School and a B.A. in molecular biology and biochemistry and economics from Rutgers University.